View in EDS

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.

Saved in:
Bibliographic Details
Title: Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Authors: Bodor JN; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA., Patel JD; Hematology Oncology Division, Northwestern University, Chicago, IL., Wakelee HA; Department of Medical Oncology, Stanford Cancer Institute, Stanford, CA., Levy BP; Department of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC., Borghaei H; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA., Pellini B; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL., Costello MR; Department of Hematology/Oncology, University of Pennsylvania Abramson Cancer Center at Chester County Hospital, West Chester, PA., Dowell JE; Department of Hematology/Oncology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX., Finley G; Department of Medical Oncology, Allegheny Health Network, Pittsburgh, PA., Huang CH; Department of Medical Oncology, University of Kansas Medical Center, Kansas City, KS., Neal JW; Department of Medical Oncology, Stanford Cancer Institute, Stanford, CA., Nieva JJ; Department of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA., Puri S; Division of Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT., Socinski MA; Department of Medical Oncology, AdventHealth Cancer Institute, Orlando, FL., Thomas C; New England Cancer Specialists, Scarborough, ME., Ross EA; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA., Litwin S; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA., Clapper ML; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA., Treat J; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: joseph.treat2@fccc.edu.
Source: Clinical lung cancer [Clin Lung Cancer] 2023 Nov; Vol. 24 (7), pp. e242-e246. Date of Electronic Publication: 2023 May 11.
Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0690
DOI:10.1016/j.cllc.2023.05.003